Johnson & Johnson stock is trading at elevated levels. Where are JNJ shares going?
What Is Johnson & Johnson’s Latest Biotech Acquisition?Johnson & Johnson is expanding its biotech portfolio with a $1 billion cash acquisition of Firefly Bio Inc. and a partnership with Sail Biomedicines that includes an option to buy the company for $2.58 billion. The Sail deal includes $785 million upfront (including a $465 million equity stake) plus $140 million tied to development milestones.Johnson & Johnson is positioning Firefly’s platform against hard-to-treat solid tumors like KRAS-driven cancers, while the deal is expected to bring an in-process R&D charge of about $1 billion in third-quarter 2026 and cut adjusted EPS by roughly $0.46 in 2026. The broader risk backdrop has also been improving after the company moved to settle outstanding talc cases, a step that can help keep focus on pipeline execution rather than litigation overhang.Critical Technical Levels For JNJ StockThe stock is consolidating near its short-term trendline, trading 0.1% below the 20-day SMA ($257.86) while holding well above the 50-day SMA ($245.23) and 200-day SMA ($226.44), which keeps the bigger uptrend intact. The 20-day SMA above the 50-day SMA, alongside the 50-day SMA above the 200-day SMA, reinforces that the longer-term bias is still bullish despite the recent pause.RSI is the cleaner momentum read right now: at 53.48, it’s neutral, suggesting the move isn’t stretched and price is more in "digest and decide" mode than breakout/flush territory. For context, RSI measures how extended buying or selling pressure is, and a mid-range reading often lines up with range trading near key moving averages.
